Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
54.97
+0.96 (1.78%)
At close: Jun 3, 2026, 4:00 PM EDT
54.97
0.00 (0.00%)
After-hours: Jun 3, 2026, 5:10 PM EDT
Royalty Pharma Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Royalty Pharma stock has a consensus rating of "Buy" and an average price target of $59.25. The average 1-year stock price forecast is 7.79% higher than the current stock price, while the lowest is $46 (-16.32%) and the highest is $66 (+20.07%).
Price Target: $59.25 (+7.79%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Royalty Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 2 | 2 | 3 |
| Hold | 1 | 0 | 1 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $63 → $64 | Buy | Maintains | $63 → $64 | +16.43% | May 7, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $50 → $58 | Buy | Maintains | $50 → $58 | +5.51% | May 7, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $54 → $62 | Buy | Maintains | $54 → $62 | +12.79% | May 7, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Reiterates $51 → $59 | Buy | Reiterates | $51 → $59 | +7.33% | May 7, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $50 | Buy | Maintains | $50 | -9.04% | May 7, 2026 |
Financial Forecast
Revenue This Year
3.43B
from 2.38B
Increased by 44.24%
Revenue Next Year
3.66B
from 3.43B
Increased by 6.67%
EPS This Year
2.56
from 1.78
Increased by 43.52%
EPS Next Year
3.73
from 2.56
Increased by 45.80%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.5B | ||
| Avg | 3.4B | ||
| Low | 3.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 47.7% | ||
| Avg | 44.2% | ||
| Low | 39.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.37 | ||
| Avg | 2.56 | ||
| Low | 1.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 89.2% | ||
| Avg | 43.5% | ||
| Low | -32.1% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.